Key result
A two-dose clinical trial of the AI-KLH conjugate vaccine resulted in a significant immune response to angiotensin I, with a shift in diastolic blood pressure dose-response in the top responder.
Why the study?
Does immunization with AI-TT or AI-KLH conjugate vaccines induce an immune response and modulate blood pressure responses to angiotensin in rats and humans?
Population
Rats and human subjects
Design
Other
Authors
Loading...
Supports further AI-KLH vaccine development for hypertension; leaves open clinical efficacy and requires larger randomized trials.
Does immunization with AI-TT or AI-KLH conjugate vaccines induce an immune response and modulate blood pressure responses to angiotensin in rats and humans?
The AI-KLH conjugate vaccine successfully induced an immune response to angiotensin I in humans, supporting its further evaluation as a potential immunotherapy for hypertension.
Downham et al. (2003) studied Hypertension. AI-KLH and AI-TT conjugate vaccines was evaluated on Immune response to angiotensin I and cardiovascular responses to AI or AII infusions. A two-dose clinical trial of the AI-KLH conjugate vaccine resulted in a significant immune response to angiotensin I, with a shift in diastolic blood pressure dose-response in the top responder.
Synapse has enriched one closely related paper. Consider it for comparative context: